Pressure ulcer
Conditions
Interventions
After 4-week untreated period, polaprezinc is administered orally at a dose of 75 mg twice a day until complete healing or for a maximum of 8 weeks.
Polaprezinc is administered orally at a dose of 75
Sponsors
Department of Public Health and Environmental Medicine, The Jikei University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet following requirements: 1) aged 20 and older 2) at least one stage 2, 3, or 4 chronic pressure ulcer according to the revised National Pressure Ulcer Advisory Panel (NPUAP) classification system 3) an estimated surface area of one ulcer is 24 square centimeters or less, as calculated with the formula: greatest length (head to toe) multiplied by greatest width (side to side) of the ulcer 4) patients who take a diet orally 5) written informed consent from patients and their families before registration to this study
Exclusion criteria
Exclusion criteria: 1) a clinical suspicion or diagnosis of osteomyelitis 2) diabetes mellitus 3) peripheral vascular disease 4) neoplastic disease 5) acute illness (e.g., infection) 6) other severe diseases 7) patients who receive tube or parenteral feeding 8) use of steroids 9) patients who are in the terminal phase of their illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in PUSH (Pressure Ulcer Scale for Healing) score | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight, Biochemistry, Dietary intake | — |
Countries
Japan
Contacts
Public ContactKensaku Sakae
The Jikei University School of Medicine Department of Public Health and Environmental Medicine
Outcome results
None listed